- Drug Pipelines
- July 2020
- 419 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- May 2023
- 106 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Drug Pipelines
- March 2021
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- April 2023
- 160 Pages
Global
From €5790EUR$5,999USD£4,967GBP
Scleroderma is a chronic autoimmune disorder that affects the skin and other organs. Dermatological drugs are used to treat the symptoms of scleroderma, including skin thickening, joint pain, and fatigue. These drugs can be divided into two categories: immunosuppressants and biologics. Immunosuppressants are used to reduce inflammation and suppress the immune system, while biologics are used to target specific proteins that are involved in the disease process.
The scleroderma drug market is highly competitive, with a number of companies offering treatments for the condition. Some of the major players in the market include Pfizer, Novartis, AbbVie, and Sanofi. These companies offer a range of treatments, including immunosuppressants, biologics, and other drugs. Additionally, there are a number of smaller companies that specialize in scleroderma treatments, such as Galapagos, FibroGen, and Fibrocell. Show Less Read more